Drug adherence and treatment duration for denosumab and mortality risk among hip fracture patients.

Yi-Lun TsaiChih-Hsing WuChia-Chun LiChien-An ShihYin-Fan ChangJawl-Shan HwangTa-Wei Tai

Published in: Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA (2023)

Better drug adherence and longer duration of denosumab treatment are associated with lower all-cause mortality risk among hip fracture patients after surgery. Our study highlights the benefits of a proper time interval of denosumab administration. These findings provide important insight into management of osteoporotic hip fractures and may inform clinical practice and development of guidelines.

Keyphrases

hip fracture
end stage renal disease
clinical practice
bone mineral density
newly diagnosed
ejection fraction
prognostic factors
peritoneal dialysis
emergency department
body composition
skeletal muscle
replacement therapy
patient reported
smoking cessation